 NEW YORK--BUSINESS WIRE--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Strongbridge Biopharma plc NASDAQ: SBBP to Xeris Pharmaceuticals, Inc. is fair to Strongbridge shareholders. Under the terms of the merger, Strongbridge shareholders will receive 0.7840 shares of the combined company and 1 contingent value right CVR for each Strongbridge share that they own. The CVR is worth up to 1.00 in cash or stock of the combined company upon achievem 